Ipamorelin 2mg
Price range: $17.56 through $175.60
Ipamorelin is a synthetic pentapeptide and highly selective agonist of the growth hormone secretagogue receptor subtype 1a (GHS-R1a). The compound is characterized by strong receptor selectivity and a well-defined pharmacological profile, making it a useful tool for investigating GHS-R1a-mediated signal transduction… CAS: 170851-70-4 | Formula: C38H49N9O5 | Content: 2 mg per vial | Research use only | Third-party lab tested.
Buy Ipamorelin 2mg – Swiss Chems USA
Ipamorelin 2mg — Research Overview
Ipamorelin is a synthetic pentapeptide and highly selective agonist of the growth hormone secretagogue receptor subtype 1a (GHS-R1a). The compound is characterized by strong receptor selectivity and a well-defined pharmacological profile, making it a useful tool for investigating GHS-R1a-mediated signal transduction and ligand-receptor interactions. Research applications include GHS-R1a pharmacology, receptor activation kinetics, signaling pathway characterization, structure-activity relationship investigations, and comparative analyses of growth hormone secretagogue receptor ligands.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
Intended use: This material is supplied for laboratory and in-vitro research only. It is not a drug, food, or cosmetic and is not intended for human or animal consumption.
Ipamorelin 2mg Chemical Properties
| Property | Specification |
|---|---|
| Chemical Formula | C38H49N9O5 |
| Synonyms | 2-Methylalanyl-L-histidyl-3-(2-naphthyl)-D-alanyl-D-phenylalanyl-L-lysinamide, 170851-70-4, C38H49N9O5, CHEMBL58547, SCHEMBL183305, SCHEMBL8169698, MolPort-039-139-953, 5020AF, ZINC29562299, AKOS030573449, DB12370, NCGC00167295-01, FT-0696037 |
| Molar Mass | 711.9 g/mol |
| CAS Number | 170851-70-4 |
| PubChem CID | 9831659 |
| Total Compound Content | 2 mg per vial |
| Shelf Life | 36 months |
Ipamorelin 2mg Research Applications
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) and highly selective agonist of the growth hormone secretagogue receptor subtype 1a (GHS-R1a). Its defining pharmacological characteristic is a high degree of receptor selectivity relative to earlier growth hormone secretagogue receptor ligands, making it a valuable tool for investigating GHS-R1a-mediated signaling pathways and ligand-receptor interactions. Activation of GHS-R1a by Ipamorelin initiates Gq/11-coupled phospholipase C signaling, resulting in IP3 and DAG second-messenger generation, intracellular calcium mobilization, and downstream signal transduction events. Pharmacokinetic investigations have characterized the compound’s receptor engagement profile and elimination dynamics in experimental systems. Research applications include GHS-R1a pharmacology, receptor activation kinetics, signal transduction characterization, structure-activity relationship investigations, and comparative analyses of selective growth hormone secretagogue receptor ligands. Supplied as a lyophilized preparation (2 mg/vial). Independently third-party HPLC-tested; COA available per batch.
Ipamorelin 2mg Lab Results & Certificates of Analysis
Third-party analytical reports associated with this research compound:
- Ipamorelin (HPLC) — September 13, 2026 | Verification
- Ipamorelin (HPLC) — September 13, 2026 | Verification
- Ipamorelin (HPLC) — June 16, 2026 | Verification
Ipamorelin 2mg Frequently Asked Questions
What makes Ipamorelin more selective than other GHS-R1a agonists?
Ipamorelin is characterized by a highly selective interaction with GHS-R1a and a well-defined pharmacological profile relative to earlier growth hormone secretagogue receptor ligands. This selectivity makes it a valuable research tool for investigating GHS-R1a-mediated signaling pathways, receptor activation kinetics, and ligand-receptor interactions without the broader receptor activity observed with less selective secretagogues.
What is the pharmacokinetic profile of Ipamorelin?
Pharmacokinetic investigations have reported a relatively short elimination profile compared with longer-acting GHS-R1a agonists. This characteristic makes Ipamorelin useful for studies examining receptor engagement dynamics, activation kinetics, signal transduction timing, and the temporal aspects of GHS-R1a-mediated signaling.
How does Ipamorelin compare with GHRH analogues in receptor pharmacology research?
Ipamorelin and GHRH analogues interact with distinct receptor systems and signaling pathways. Ipamorelin acts through GHS-R1a, whereas compounds such as CJC-1295 and Sermorelin target the growth hormone-releasing hormone receptor (GHRHR). Comparative investigations utilize these compounds to examine differences in receptor activation mechanisms, downstream signaling architecture, ligand selectivity, and pathway-specific signal transduction.
Research Use Disclaimer
All product information is provided for educational and laboratory research reference only. Any form of introduction into humans or animals is prohibited. Handle only in licensed research settings in accordance with applicable laws and institutional protocols.
| Weight | 1 lbs |
|---|---|
| Ipamorelin 2Mg |
1 vial ,KIT (10 vials) |
Related products
Cibinitide ARA-290 16mg
Price range: $85.60 through $855.95
CJC-1295 with DAC, 2mg
Price range: $47.95 through $479.50
CJC-1295 without DAC 2 mg
Price range: $42.95 through $429.50
Delta Sleep-Inducing Peptide (DSIP) 2mg
Price range: $24.95 through $249.50
Epitalon 10 mg
Price range: $23.16 through $231.60
FTPP (Adipotide) 5mg
Price range: $63.95 through $639.50
Reviews
There are no reviews yet.